TOPNewsFiscal 2025Asahi Kasei Pharma selects MAIA Pharmaceuticals to Advance Teribone™ for U.S. osteoporosis patients

  • Press Releases

Asahi Kasei Pharma selects MAIA Pharmaceuticals to Advance Teribone™ for U.S. osteoporosis patients

Maximizing the global value through out-licensing of a proven bone-forming proprietary product optimized for real-world use

February 19, 2026
Asahi Kasei Pharma Corp.

Asahi Kasei Pharma announces that it has selected MAIA Pharmaceuticals, Inc. as its U.S. partner under a strategic collaboration for the development and commercialization in the U.S. of Teribone™ osteoporosis drug (generic name: teriparatide acetate; product name in Japan: “Teribone™ 56.5 µg subcutaneous injection” and “Teribone™ 28.2 µg subcutaneous injection autoinjector”).

Under the collaboration framework, MAIA will leverage its U.S. regulatory, clinical and development capabilities to support the future development and commercialization of Teribone™ in the United States, with Asahi Kasei Pharma granting MAIA the right to a future license to develop Teribone™ and obtain marketing approval, subject to customary conditions.

Asahi Kasei positions its Pharmaceuticals business as one of its First Priority businesses in its “Trailblaze Together” medium-term management plan for fiscal 2025–2027. Since its approval in 2011 as a treatment promoting bone formation, Teribone™ has been widely used to help treat patients throughout Japan.

Over 10 million diagnosed and an estimated 44 million at risk people in the U.S. are reported to have osteoporosis.* As the population continues to age, the number of osteoporosis patients in the U.S. is expected to grow significantly. Osteoporotic fractures remain a leading cause of hospitalization, disability, and loss of independence among older adults. Osteoporosis can lead to fractures in the spine and femoral neck, often resulting in patients being confined to bed. Osteoporosis is thus regarded as an important medical and societal issue. Through collaboration with MAIA, Asahi Kasei Pharma aims to expand access in the United States to a proven bone-forming therapy, for a large and growing patient population at risk of fracture.

Asahi Kasei Pharma aims to realize a society where “no one should have to give up doing what they love due to illness” by providing osteoporosis therapy in accordance with its mission “to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science.” This collaboration represents a strategic step toward extending that mission beyond Japan to patients in the United States.

About Teribone™
Teribone™ is a human parathyroid hormone (PTH) preparation developed by Asahi Kasei Pharma to promote bone formation. With weekly or twice-weekly administration, it improves bone quality and increases bone mass, thereby enhancing bone strength while reducing the risk of fracture.
About MAIA Pharmaceuticals, Inc.
MAIA Pharmaceuticals is a specialty pharmaceutical company focused on advancing differentiated and clinically meaningful therapies, with particular expertise in U.S. regulatory development, lifecycle optimization, and commercialization of complex and value-enhanced medicines.